Please use this identifier to cite or link to this item:
Title: Quality by Design of Pranoprofen Loaded Nanostructured Lipid Carriers and Their Ex Vivo Evaluation in Different Mucosae and Ocular Tissues
Author: Rincón, María
Espinoza, Lupe Carolina
Silva Abreu, Marcelle
Sosa Díaz, Lilian Elisa
Pesantez Narvaez, Jessica Estefania
Abrego Escobar, Guadalupe
Calpena Campmany, Ana Cristina
Mallandrich Miret, Mireia
Keywords: Nanopartícules
Agents antiinflamatoris
Antiinflammatory agents
Issue Date: 24-Sep-2022
Publisher: MDPI
Abstract: Transmucosal delivery is commonly used to prevent or treat local diseases. Pranoprofen is an anti-inflammatory drug prescribed in postoperative cataract surgery, intraocular lens implantation, chorioretinopathy, uveitis, age-related macular degeneration or cystoid macular edema. Pranoprofen can also be used for acute and chronic management of osteoarthritis and rheumatoid arthritis. Quality by Design (QbD) provides a systematic approach to drug development and maps the influence of the formulation components. The aim of this work was to develop and optimize a nanostructured lipid carrier by means of the QbD and factorial design suitable for the topical management of inflammatory processes on mucosal tissues. To this end, the nanoparticles loading pranoprofen were prepared by a high-pressure homogenization technique with Tween 80 as stabilizer and Lanette® 18 as the solid lipid. From, the factorial design results, the PF-NLCs-N6 formulation showed the most suitable characteristics, which was selected for further studies. The permeability capacity of pranoprofen loaded in the lipid-based nanoparticles was evaluated by ex vivo transmucosal permeation tests, including buccal, sublingual, nasal, vaginal, corneal and scleral mucosae. The results revealed high permeation and retention of pranoprofen in all the tissues tested. According to the predicted plasma concentration at the steady-state, no systemic effects would be expected, any neither were any signs of ocular irritancy observed from the optimized formulation when tested by the HET-CAM technique. Hence, the optimized formulation (PF-NLCs-N6) may offer a safe and attractive nanotechnological tool in topical treatment of local inflammation on mucosal diseases.
Note: Reproducció del document publicat a:
It is part of: Pharmaceuticals, 2022, vol. 15(10), num. 1185, p. 1-24
Related resource:
ISSN: 1424-8247
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
725173.pdf3.61 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons